Scribe Therapeutics (SCTX) Director Behzad Aghazadeh Receives Award

What Happened
Behzad (Dr.) Aghazadeh, a director of Scribe Therapeutics (SCTX), was granted 14,725 derivative shares (reported as an award, code A) on July 23, 2026. The filing reports an acquisition price of $0.00 (no cash paid at grant). Footnotes indicate these are subject to a vesting schedule: 1/3 of the total shares vest on each of July 23, 2027, July 23, 2028 and July 23, 2029, contingent on continued service.

Key Details

• Transaction date: 2026-07-23; reported on Form 4 filed 2026-07-27 (timely filing).
• Security: 14,725 derivative shares granted; reported price $0.00 (award/grant).
• Vesting: 1/3 each year on 7/23/2027, 7/23/2028, and 7/23/2029 (service condition).
• Ownership after transaction: not specified in the provided filing details.
• Reporting persons: Form 4 filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, and Avoro Ventures LLC; Dr. Aghazadeh is portfolio manager and controlling person of the Avoro entities (footnotes disclaim full beneficial ownership except for pecuniary interest).
• Remarks note Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the issuer.

Context
This was a grant of derivative securities (likely stock options or similar awards) rather than an open‑market purchase or sale, meaning no immediate cash changed hands and no shares were sold. Such awards typically vest over time and are conditional on continued service, so they do not indicate an immediate change in insider holdings available for sale.